Articlebronze2006

How much will Herceptin really cost?

Ann Barrett · Tom W. Roques · Matthew Small · Richard Smith

101 citations0/0 files storedBMJ

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Economic and Financial Impacts of Cancer

Abstract

New guidance from the National Institute for Health and Clinical Excellence recommends Herceptin in early breast cancer, but it provides no additional funding or any suggestion of which services to cut. This leaves medical staff with difficult decisions to make

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 101 citations exist upstream.

References

2004National Institute for Clinical Excellence and its value judgments 2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis 2004Health care priority setting: principles, practice and challenges 1993Economics of Health Care Financing: The Visible Hand 2005“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making

Cited by

2009Soft regulations in pharmaceutical policy making 2008Recent National and Regional Drug Reforms in Sweden 2024Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis 2011European countries with small populations can obtain low prices for drugs: Lithuania as a case history 2011Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications 2018The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.